Staphylococcus Aureus Network Adaptive Platform Trial

Summary

The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).

Conditions

• Staphylococcus Aureus Bacteremia

Interventions

DRUG

Cefazolin

Cefazolin

DRUG

Penicillin

benzylpenicillin

DRUG

Clindamycin

Clindamycin

DRUG

Vancomycin

Vancomycin or Daptomycin

OTHER

Effectiveness of early switch to oral antibiotics

This involves testing a strategy rather than individual antibiotic agents

RADIATION

Whole body FDG PET/CT Imaging

Whole body FDG PET/CT imaging will be performed using a standardised protocol describing patient preparation and minimum specifications for radiopharmaceutical production, quality control, and PET/CT acquisition.

Sponsors & Collaborators

• Berry Consultants

  collaborator OTHER

• McGill University Health Centre/Research Institute of the McGill University Health Centre

  collaborator OTHER

• Menzies School of Health Research

  collaborator OTHER

• Aotearoa Clinical Trials

  collaborator OTHER

• Queensland University of Technology

  collaborator OTHER

• Sunnybrook Health Sciences Centre

  collaborator OTHER

• Tan Tock Seng Hospital

  collaborator OTHER

• Telethon Kids Institute

  collaborator OTHER

• The Peter Doherty Institute for Infection and Immunity

  collaborator OTHER

• The University of Queensland

  collaborator OTHER

• UMC Utrecht

  collaborator OTHER

• Radboud University Medical Center

  collaborator OTHER

• King's College London

  collaborator OTHER

• Rambam Health Care Campus

  collaborator OTHER

• University College, London

  collaborator OTHER

• The Methodist Hospital Research Institute

  collaborator OTHER

• University of Melbourne

  lead OTHER

Principal Investigators

• Prof Steven Tong · University of Melbourne / Melbourne Health

• Prof Joshua Davies · Menzies School of Research / Hunter New England Medical Centre

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

FACTORIAL

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-02-16

Primary Completion

2028-12-01

Completion

2028-12-01

Countries

• United States
• Australia
• Canada
• France
• Germany
• Israel
• Japan
• Netherlands
• New Zealand
• Singapore
• South Africa
• Sweden
• United Kingdom

Study Locations